ZURICH/BERLIN, Apr 24(Reuters) -Here are some of the main factors that may affect Swiss stocks on Wednesday:

NOVARTIS NOVN.S

Novartis has been hit with a lawsuit by people with autism and their mothers alleging the drugmaker illegally promoted an asthma drug for treatment of preterm labor despite knowing it was ineffective and could cause abnormal fetal brain development.

COMPANY STATEMENTS

* Galderma Group AG - 2024 Full Year Guidance Confirmed

* Temenos AG TEMN.S - Names new CEO Jean-Pierre Brulard

* Temenos AG TEMN.S - Q124 Total Revenues 229.9 Million USD

* Novartis AG - Novartis And Medicines For Malaria Announce Positive Trial Results For Novel Malaria Treatment For Babies

ANALYSTS' VIEWS

NOVARTIS AG - JP MORGAN RAISES TARGET PRICE TO CHF 95 FROM 90

TEMENOS AG - JP MORGAN CUTS TARGET PRICE TO CHF 84 FROM CHF 101

ANNUAL GENERAL MEETINGS

BACHEM BANB.S - 0.8 CHF/shr dividend proposed

SFS GROUP SFSN.S - 2.5 CHF/shr dividend proposed

UBS GROUP UBSG.S - 0.61 CHF/shr dividend proposed

CEMBRA MONEY BANK CMBN.S - 4 CHF/shr dividend proposed

EX-DIVIDEND

FLUGHAFEN ZUERICH FHZN.S - 5.3 CHF/shr dividend

BKW BKWB.S - 3.4 CHF/shr dividend

ECONOMY

Swiss April Investor Sentiment due at 0800 GMT

Reporting by Zurich newsroom and Berlin Speed Desk

For Top News in a multimedia Web format on Eikon visit: https://bit.ly/2NDFd6g

FOR RELATED PRICES, NEWS AND OTHER TOPICS, DOUBLE-CLICK ON:
Daily Swiss stock market report in German .SDE
All SMI constituent stocks 0#.SSMI
DJ STOXX index .STOXX
Top 10 STOXX sectors .PGL.STOXXS
Top 10 EUROSTOXX sectors .PGL.STOXXES

Swiss mid-cap index .SSMI
Swiss all-share index .SSHI
Swiss market digest .AD.S
Sector overview CH/SECTOR1
All Swiss news CH
Swiss research news CH-RCH 
All equity news E

SPEED GUIDES: EQUITY, EQUITY/NEWS1, EUR/EQUITY, SWITZERLAND, REUTERS